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Abstract
Objective
HIV controllers (HICs) spontaneously maintain HIV viral replication at low level without
antiretroviral therapy (ART), a small number of whom will eventually lose this ability to
control HIV viremia. The objective was to identify factors associated with loss of virologi-
cal control.
Methods
HICs were identified in COHERE on the basis of 5 consecutive viral loads (VL) 500
copies/mL over 1 year whilst ART-naive, with the last VL 500 copies/mL measured 5
years after HIV diagnosis. Loss of virological control was defined as 2 consecutive VL
>2000 copies/mL. Duration of HIV control was described using cumulative incidence
method, considering loss of virological control, ART initiation and death during virological
control as competing outcomes. Factors associated with loss of virological control were
identified using Cox models. CD4 and CD8 dynamics were described using mixed-effect
linear models.
Results
We identified 1067 HICs; 86 lost virological control, 293 initiated ART, and 13 died during
virological control. Six years after confirmation of HIC status, the probability of losing virolog-
ical control, initiating ART and dying were 13%, 37%, and 2%. Current lower CD4/CD8 ratio
and a history of transient viral rebounds were associated with an increased risk of losing
virological control. CD4 declined and CD8 increased before loss of virological control, and
before viral rebounds.
Discussion
Expansion of CD8 and decline of CD4 during HIV control may result from repeated low-level
viremia. Our findings suggest that in addition to superinfection, other mechanisms, such as
low grade viral replication, can lead to loss of virological control in HICs.
Introduction
Natural history of HIV-1 infection is characterized by a gradual loss of CD4 cells, a persistent
elevation of CD8 cells, together with an increase of HIV RNA viral load [1–3]. However, some
HIV-1-positive individuals spontaneously control HIV replication in the absence of antiretro-
viral therapy (ART): they are referred to as HIV controllers (HICs) [4,5]. Although a large pro-
portion of HICs do not appear to experience disease progression [6], a small number of HICs
will eventually progress with CD4 decline and/or loss of virological control [7–11]. Very few
studies have focused on the factors associated with loss of virological control, since the event is
rarer than immunological progression in HICs [10]. Association with age, mode of HIV acqui-
sition, total cell-associated HIV DNA, duration of HIV infection, or HCV coinfection were
inconsistently identified with discrepancies on the magnitude of their effect, probably because
Loss of virological control among HIV controllers
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of the limited number of HICs included in most of these studies [7–10]. Whilst low or declin-
ing CD4 counts have been associated with loss of virological control in HICs [7,8], the con-
comitant evolution of CD8 count during HIV control has never been investigated, despite the
pivotal role of effective HIV-specific CD8 response in virological control [5,12–17].
The objectives of the present study were to describe the incidence of, and identify factors
associated with, loss of virological control in 1067 HICs from the large European COHERE in
Eurocoord collaboration of cohorts. We also modeled the evolution of CD4 counts, CD8 counts
and CD4/CD8 ratio during virological control preceding the outcomes of virological control.
Patients and methods
Eligible population in the COHERE dataset
The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) is a col-
laboration of 40 HIV cohorts (circa 2015) within the EuroCoord network (www.cohere.org;
www.Eurocoord.net) representing over 330,000 HIV-1-positive individuals. The HIV controllers
project was endorsed by 28 cohorts and the dataset pooled in 2014 included 216,614 patients.
Eligible HIV-positive individuals from the COHERE database were those who had at least 5
HIV RNA viral load (VL) measurements, were followed for more than 5 years after HIV diag-
nosis, were enrolled after 01/01/1996 and less than 8 years after HIV diagnosis and were aged
15 years or more at diagnosis. Enrolment date was defined as the earliest of the date of first
CD4 cell counts or first VL measurement.
Definition of HIV controllers
HICs were eligible individuals who had at least 5 consecutive VL500 copies/mL whilst ART-
naive, over a period of at least 1 year, with the last VL500 copies/mL being at least 5 years
after HIV diagnosis. These criteria were based on the ANRS definition of HICs [18]. This defi-
nition also allowed to identify HIV controllers followed at calendar periods before assays with
thresholds of 40 copies became widely available. The first of the VL500 copies/mL defined
the start of the observed period of HIV virological control. The 5th consecutive VL500 cop-
ies/mL, or the nth (n>5) if the 5th was within 1 year after the 1st VL500 copies/mL or less
than 5 years after HIV diagnosis, defined the date of confirmation of HIC status [19]. Virologi-
cal control ended at the first of the following events: 1) confirmed loss of virological control
defined as 2 consecutive VL>2000 copies/mL, 2) ART initiation, 3) death or 4) end of follow-
up while still experiencing virological control.
Individuals who experienced within a 6 month-period a spontaneous drop of VL at least 2
log10 copies/mL from an initial VL>5.3 log10 copies/mL, concomitantly with an increase of at
least 100 CD4/mm3, were suspected of having received unreported ART and were not consid-
ered as HIC. Similarly, individuals with an AIDS-related illness before confirmation of HIC
status were not considered as HICs as they were expected to have initiated ART.
Statistical analyses
Data were expressed as median (interquartile range (IQR)) for continuous variables and % (n)
for categorical variables.
Loss of virological control, ART initiation and death were considered as competing out-
comes in this study. The probabilities [95% confidence interval (CI)] of loss of virological con-
trol, ART initiation or death at different times after confirmation of HIC status were estimated
using cumulative incidence functions, based on the Fine and Gray model for handling compet-
ing events in a survival analysis [20].
Loss of virological control among HIV controllers
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Factors associated with loss of virological control, or with ART initiation, were identified
using cause-specific Cox models, with right-censoring of follow-up in individuals having experi-
enced one of the other competing events. Cox models were stratified by cohort and set with the
origin at confirmation of HIC status. In addition to baseline covariates, time-updated categorical
covariates were included in the analysis to estimate the effect of current age (50 and>50
years), current calendar period of follow-up (<2003, 2003–2007 and>2007), current CD4 count
(350, 351–500 and>500 cells/mm3), current CD8 count (600, 601–1200,>1200 cells/mm3)
and current CD4/CD8 ratio (0.50, 0.51–0.80, 0.81–1 and>1) on the outcome. Current CD4,
CD8 and CD4/CD8 values were defined as the most recent available values during virological
control in a time-updated manner. Of note, 7 cohorts did not report CD8 counts. VL>500 cop-
ies/mL during virological control were defined as viral rebounds. Any viral rebound followed by
a VL500 copies/mL during virological control was designated as a ‘transient’ rebound. A
time-updated variable describing the history of viral rebounds took the following values: 0 before
any rebound, 1 after the first transient rebound, 2 after subsequent transient rebounds, and 3
during a rebound (S1 Fig); this variable was considered as a categorical variable in the models.
All variables with univariate p-value<0.1 were included in the multivariate models.
Cox models correcting for competing events using the Fine and Gray method [21] or
inverse probability weighting [22,23] were also performed and produced similar results. Sensi-
tivity analyses were conducted: i) restricting the analysis to men in order to remove women
who would have initiated ART for the sole purpose of prevention of mother-to-child transmis-
sion, and ii) excluding HICs with less frequent VL monitoring during virological control (with
at least one time interval between 2 consecutive VLs that was greater than 2 years).
The dynamics of CD4 count, CD8 count and the CD4/CD8 ratio during virological control
were described using mixed-effect linear models in order to take into account the correlation
between measurements from the same patient. Square root transformations for CD4 and CD8
counts were used to fulfill the model assumptions. The models included fixed and random
effects for both the intercept and slopes (unstructured covariance). The CD4, CD8 and CD4/
CD8 dynamics were described over the last five years preceding loss of virological control,
ART initiation, death, or censoring. Finally, in order to investigate the association between the
occurrence of viral rebounds and the evolution of immunologic markers during virological
control, the dynamics of CD4 count, CD8 count and CD4/CD8 were compared before and
after occurrence of the first viral rebound; in that case, the study period was restricted to the 5
years before and 2 years after the first viral rebound. For these analyses, only HICs with both
CD4 and CD8 values available over the relevant periods were considered. However, we verified
that the predicted CD4 dynamics in these models were similar with respect to the mean inter-
cept and slope estimates when all HICs were considered.
All analyses were performed using Stata 14 (StataCorporation, College Station, Texas,
USA), but the cumulative incidence functions were estimated using R (https://R-project.org).
Ethical considerations
In COHERE, data storage, management and handling are protected in accordance with the
European Commission Directive 95/46/EC and appropriate national regulations. Ethical
requirements fall within the individual cohort’s ethics.
Results
Characteristics of HIV controllers
We identified 1067 HICs among the 111,073 eligible individuals (0.96%) (S2 Fig). Table 1
shows the main characteristics of HICs and non-HICs. The proportion of women was higher
Loss of virological control among HIV controllers
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among HICs than non HICs (42.2% and 29.2%, respectively), and the proportion of men hav-
ing sex with men (MSM) among men was lower (48.8% and 56.1%, respectively) (Table 1).
The proportion of injecting drug users (IDU) was slightly higher among HICs (12.3% and
10.4%, respectively). Median age at HIV diagnosis for HICs and non-HICs was 33 and 34
years, respectively. At enrolment, CD4 counts were higher and CD8 counts lower among
HICs than non-HICs (669 and 333 CD4/mm3, and 788 and 850 CD8/mm3, respectively).
Median CD4/CD8 ratio was higher among HICs than non-HICs (0.84 and 0.36, respectively).
Only 15,552 (14%) of the 111,073 eligible individuals had test results available to determine
their HCV status in COHERE database. Among those with a known HCV status, HIV-HCV
coinfection was identified in 69.7% of HICs and 59.5% of non-HICs (data not shown).
Among the 1067 HICs, 86 experienced loss of virological control, 293 initiated ART and 13
died during virological control (3 from non-AIDS defining infections, 2 cardiovascular dis-
eases, 1 chronic hepatitis C, 1 carcinoma, 1 mental disorder related to drug abuse and 5
unknown/unreported causes of death). The remaining 675 HICs maintained virological con-
trol up to the end of follow-up and their follow-up was therefore right-censored.
The probabilities of loss of virological control 2, 6 and 10 years after confirmation of HIC
status were 2.0%, 12.8% and 19.0%, respectively (Fig 1). The corresponding probabilities for
ART initiation and death during virological control are illustrated in Fig 1. Altogether, the
probabilities of maintaining HIC status 2, 6 and 10 years after confirmation of HIC status were
78.0% [75.1–80.7], 48.4% [44.1–52.6] and 29.2% [23.6–34.9], respectively.
During virological control, 310 HICs (29.1%) experienced viral rebounds, including 167
(15.7%) with transient rebounds (Table 2). The median delay from the confirmation of HIC
status to the first rebound was 1.2 years in those who experienced rebounds. The median
(IQR) maximum level reached during viral rebound was 1140 (710–1980) copies/ml.
During virological control, 4 HICs had no CD4 measurements and 261 HICs had no CD8
measurements. In HICs with measurements, the median (IQR) number of VL, CD4 and CD8
measurements during virological control were 11 (8–16), 12 (8–17) and 11 (7–16),
Table 1. Characteristics of HIV controllers and non-HIC from COHERE eligible patients.
HICs Non-HICs
N = 1067 N = 110,006
% (n) % (n)
Women 42.2 (450) 29.2 (32,099)
Mode of HIV acquisition
IDU 12.3 (131) 10.4 (11,436)
MSM 28.2 (301) 39.7 (43,671)
Other sexual contact 48.9 (522) 42.4 (46,686)
Other or unknown 10.6 (113) 7.5 (8,213)
Age at HIV diagnosis (years) 33 (28–40) 34 (28–41)
Duration of follow-up (years) 8.5 (6.3–11.9) 8.9 (6.4–12.2)
CD4 cell count at enrolment (cells/mm3)a 669 (490–887) 333 (163–520)
CD8 cell count at enrolment (cells/mm3)b 788 (587–1092) 850 (584–1210)
CD4/CD8 ratio at enrolment (cells/mm3)c 0.84 (0.58–1.18) 0.36 (0.19–0.60)
Data are median (IQR) or % (n); HICs, HIV controllers; IDU, injecting drug users; MSM, men having sex with men.
a Closest CD4 measurement available in the following 6 months, 27 and 2997 missing values among HIC and non-HIC
b Closest CD8 measurement available in the following 6 months, 388 and 43,763 missing values among HIC and non-HIC
c Closest CD4/CD8 values available in the following 6 months, 389 and 43,763 missing values among HIC and non-HIC
https://doi.org/10.1371/journal.pone.0173893.t001
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respectively; the median time interval between each pair of consecutive measurements for VL,
CD4 and CD8 was 5.0 (3.4–6.9), 4.7 (3.3–6.5) and 4.6 (3.2–6.5) months, respectively.
Median CD4 counts at the end of the period of virological control were lower in those who
lost virological control, initiated ART or died, compared to those still in virological control
(515, 412, 527, and 711 CD4/mm3, respectively) (Table 2). Median CD8 counts were higher in
those who lost virological control compared to those who initiated ART, died or remained in
virological control (1006, 780, 714, and 837 CD8/mm3, respectively).
Factors associated with loss of virological control
In univariate Cox analysis, men were at a higher risk of losing virological control than women
(Table 3). Our large sample of HIC allowed us to attempt to unravel the role of gender from
the role of the mode of HIV acquisition. Compared to non-IDU women, IDU men or IDU
women did not appear to be at greater risk of losing virological control, while non-IDU men
(either MSM or MSW) were at higher risk of losing virological control. Of note, median (IQR)
time between VL measurements during virological control was 4.9 (3.4–6.7) months in non-
Fig 1. Cumulative incidence functions for loss of virological control, ART initiation and death since confirmation of HIV
controller status.
https://doi.org/10.1371/journal.pone.0173893.g001
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IDU men and 5.1 (3.5–7.1) months in non-IDU women (p = 0.01). This could have introduced
a bias as non-IDU men were monitored more frequently than non-IDU women, which in turn
could have explained the greater odds of loss of control in non-IDU men. However, in a sensi-
tivity analysis excluding HICs with less frequent VL monitoring during virological control (at
least one time interval between 2 consecutive VLs> 2 years), similar results were obtained, i.e.
Table 3. Factors associated with loss of virological control in 1067 HIV controllers from the COHERE Collaboration.
1067 HICs Univariate analysis * Multivariate analysis *
person-years (3173) Virological loss (n = 86) Crude HR [95% CI] p Adjusted HR [95% CI] P
Gender 0.013
Women 1381 27 1
Men 1792 59 1.81 [1.12–2.94]
Mode of HIV acquisition by gender 0.031 0.11
IDU women 118 3 1.13 [0.32–4.04] 1.53 [0.31–7.61]
IDU men 331 5 0.68 [0.25–1.87] 0.51 [0.15–1.73]
MSM 933 36 2.11 [1.20–3.71] 2.24 [1.15–4.34]
MSW 383 14 2.16 [1.08–4.34] 1.28 [0.51–3.23]
Non-IDU women 1161 24 1 1
Other or unknown 247 4 0.95 [0.32–2.85] 1.41 [0.39–5.04]
Current age ‡ 0.59
50 years 2515 69 1
>50 years 658 17 0.86 [0.48–1.52]
Current period of follow-up ‡ 0.42
<2003 384 11 1
2003–2007 1314 36 0.61 [0.29–1.29]
>2007 1475 39 0.61 [0.28–1.29]
Current CD4 level (cells/mm3)‡ 0.006 0.008
>500 2383 50 1 1
351–500 542 27 2.36 [1.42–3.90] 2.57 [1.41–4.67]
350 240 8 1.48 [0.68–3.21] 1.32 [0.53–3.30]
Current CD8 level (cells/mm3) ‡ 0.016 0.26
600 565 6 1 1
601–1200 1247 36 2.46 [1.02–5.92] 1.33 [0.53–3.30]
>1200 574 24 3.38 [1.35–8.44] 1.98 [0.76–5.15]
Current CD4/CD8 ratio level ‡ <0.0001
>1 873 10 1
0.81–1 307 4 1.02 [0.31–3.34]
0.51–0.80 680 26 3.26 [1.55–6.87]
0.50 523 26 4.48 [2.10–9.56]
History of viral rebounds ‡ <0.0001 <0.0001
Before any rebound 2533 21 1 1
After the 1st transient rebound 193 5 2.84 [1.04–7.79] 1.90 [0.53–6.82]
After subsequent transient
rebounds
53 4 7.99 [2.32–27.46] 9.24 [2.42–35.36]
During a rebound 394 56 12.95 [7.49–22.37] 12.15 [6.38–23.13]
HICs, HIV controllers; IDU, injecting drug users; MSM, men having sex with men; MSW, men having sex with women.
* Stratified on cohort
‡ Time-updated covariates
https://doi.org/10.1371/journal.pone.0173893.t003
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non-IDU men were at a higher risk of losing virological control than non-IDU women. When
compared to those with a CD4 >500 cells/mm3, individuals with a current CD4 count of 351–
500 cells/mm3 had an increased risk of losing virological control, while those with a current
CD4 count350 cells/mm3 did not. Individuals with higher current CD8 counts had an
increased risk of losing virological control. Individuals with a current CD4/CD8 ratio between
0.51 and 0.80 had an increased risk of losing virological control when compared to those with
a ratio >1; the risk was even higher among those with a ratio0.5. The risk of loss of virologi-
cal control was increased after the 1st transient viral rebound, compared with no rebound, and
was even higher after subsequent transient rebounds. Age at diagnosis, current age and current
period of follow-up were not associated with increased risk of losing virological control.
In multivariate analysis, transient viral rebounds, a current CD4 count of 351–500 cells/
mm3 and MSM mode of acquisition remained independently associated with an increased risk
of losing virological control (Table 3). Higher CD8 counts were no longer statistically signifi-
cant after adjustment for viral rebounds. In sensitivity analysis restricted to men, transient
viral rebounds and a current CD4 count between 351 and 500 cells/mm3 were associated with
a higher risk of losing virological control in multivariate analysis.
Factors associated with ART initiation
Since ART initiation was a major competing event (n = 293), factors associated with this out-
come were investigated. In univariate Cox analysis, decreasing current CD4 levels were associ-
ated with increasing chance of ART initiation, as expected. Lower current CD4/CD8 ratio and
more recent calendar period were also associated with a higher chance of ART initiation (S1
Table). Individuals with transient viral rebounds were more likely to initiate ART, although
the HRs were lower than those observed for loss of virological control. Current CD8 level was
not associated with an increased uptake of ART.
CD4 and CD8 dynamics during virological control
For 806 HICs who had both CD4 and CD8 measurements during the whole period of virologi-
cal control, the mean CD4 and CD8 levels at the observed start of virological control, estimated
with a linear mixed effect model, were 26.51
p
CD4/mm3 (i.e. 703 CD4/mm3) and 29.46
p
CD8/mm3 (i.e. 868 CD8/mm3) respectively. Overall, during virological control, CD4 counts
decreased significantly by a mean of -0.16
p
cells/mm3/year (p<0.001) whereas CD8 counts
tended to increase (+0.06
p
cells/mm3/year; p = 0.07). The estimated mean CD4/CD8 ratio
was 0.94 at the beginning of the period of virological control and decreased significantly by
-0.01 per year (p<0.001).
CD4 and CD8 dynamics according to outcome of virological control
The progression of CD4, CD8 and CD4/CD8 ratio over the 5 years preceding the end of viro-
logical control, or end of follow-up for those who maintained virological control, were
described (Fig 2) (S2 Table) in 794 HICs with both CD4 and CD8 measurements available.
CD4, CD8 and CD4/CD8 slopes were not significantly different from zero in those who died
during virological control but the sample was small (n = 9). Mean CD4 decline was signifi-
cantly greater in those who initiated ART (n = 227) or lost virological control (n = 66) than in
those who maintained virological control at the end of follow-up (n = 492). At the end of the
period of virological control, CD4 level was lower in those who initiated ART than in those
who lost virological control, and was higher in those who maintained virological control.
Mean CD8 counts increased significantly in those who experienced loss of virological control
whereas it remained stable in the other groups. The CD8 level at the end of the period of
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virological control was much higher in those who experienced loss of virological control.
Mean CD4/CD8 ratio also decreased significantly in those who experienced loss of virological
control, and to a lesser extent in those who had maintained virological control at the end of fol-
low-up. The ratio was stable in those who initiated ART.
We further investigated if the rates of change of CD4, CD8 or CD4/CD8 differed during the
year preceding loss of virological control as compared to prior this one-year period. We could
not identify a significant change of the slope for CD8 or for CD4/CD8 ratio. On the other
hand, during the year preceding loss of virological control, the CD4 decrease was significantly
steeper than during the period further before (-1.51
p
cells/mm3/year and -0.38
p
cells/mm3/
year, respectively; p = 0.026).
CD4 and CD8 dynamics according to occurrence of viral rebounds
For 247 HICs who experienced viral rebounds during virological control, we investigated CD4
and CD8 dynamics before and after the occurrence of the first viral rebound. We restricted the
analysis to the 5 years before and 2 years after the first viral rebound. Mean CD4 counts decreased
significantly prior to the first viral rebound by -0.52
p
cells/mm3/year and continued to decrease
at the same pace afterwards (comparison of 1st and 2nd slopes: p = 0.74). Similarly, mean CD8
counts increased significantly prior to occurrence of the first viral rebound by +0.31
p
cells/
mm3/year and continued to increase at the same pace afterwards (p = 0.56). Mean CD4/CD8
ratio decreased significantly prior to the first viral rebound by -0.037 per year and continued to
decrease at the same pace afterwards (p = 0.44). We also investigated if the rates of change of
CD4, CD8 or CD4/CD8 differed during the year preceding the first viral rebound as compared
to prior this one-year period. We could not identify a significant change of the slope for CD8 or
for CD4/CD8 ratio. Regarding the CD4 progression, the decrease was significantly steeper during
the year preceding the first rebound compared to earlier (p<0.001).
Discussion
In this study we identified 1067 HICs, representing 1% of eligible individuals. This is, to date,
the largest series of HIV controllers, internationally. This allowed us to study the incidence of
and risk factors for loss of virological control, which had rarely been done. Over a follow-up
period to 2014, the risk of losing virological control remained relatively low over time, com-
pared with the main competing event signifying the end of the period of virological control,
i.e. ART initiation. For example, 6 years after confirmation of HIC status, the probability for
HICs of maintaining virological control was 48%, with a probability of losing virological con-
trol of 13% and a much higher probability of initiating ART of 37%.
Men, either MSM or MSW, were at a higher risk of losing virological control than non-
IDU women or IDU men and women in univariate analysis, even when restricting the analysis
to HIC with regular VL monitoring. Some MSW in our study may have chosen not to report a
sexual preference for men, but it is unlikely that any under-reporting would be large enough to
explain this finding. We and other authors previously described an over-representation of
IDUs and an under-representation of MSM among HICs compared to non-HICs [16,6];
another HIC study also found that MSM were at greater risk of virologic and immunologic
progression than IDU [7]. A potential explanation for this increased risk could be a higher risk
of sexually acquired super-infection, which has been reported to lead to loss of control among
elite controllers [25–27], or active coinfections. In natural history studies, women have been
reported to have lower viral load than men at the same time after infection [28,29]. We can
therefore hypothesize that women maintain this advantage during spontaneous virological
control.
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Other factors associated with the risk of losing virological control were a current CD4
count between 350 and 500/mm3, current higher CD8 counts or lower CD4/CD8 ratio, and a
history of transient viral rebounds during control. Of note, a CD4 level below 350 cells/mm3
was not associated with an increased risk of losing virological control, most likely because
HICs presenting with low CD4 counts initiated ART before loss of virological control could be
observed, in line with guidelines [30,31]. In multivariate analysis, a current CD4 count
between 350 and 500/mm3 and a history of transient viral rebounds remained independently
associated with the risk of losing virological control.
Modeling CD4 and CD8 counts during the 5 years preceding the end of virological control
allowed us to describe with greater precision the dynamics of these cells before the outcome. A
significant CD8 count increase was observed in those who subsequently lost virological control
but not in the other groups; this finding has never been described to date. We observed a simi-
lar CD4 count decrease in those who lost control or initiated ART, with the latter group having
lower absolute counts. Interestingly, CD4 counts also decreased in those who maintained viro-
logical control at the end of follow-up, around 9 cells/year, albeit at a slower pace than during
Fig 2. Immunologic evolution during the last 5 years of HIV control according to the event ending virological control (in 794 HIV controllers with
both CD4 and CD8 measurements during this period).
https://doi.org/10.1371/journal.pone.0173893.g002
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natural history [32]. The association between CD4 decline and occurrence of blips during HIV
control has been previously described [9,10,12], but here, and for the first time to our knowl-
edge, we were able to model lymphocyte count dynamics before and after viral rebounds. We
showed that CD4 counts and CD4/CD8 ratio declined several years before the first viral
rebound was clinically observed. These findings suggest that super-infections are not the only
mechanism leading to loss of control in HICs.
Our results are consistent with a role of chronic immune activation, inversely correlated
with CD4 cell counts and positively correlated with CD8 counts. It was recently shown that
high levels of T cell activation and inflammation parameters were associated with disease pro-
gression among HICs [10]. Viral rebound history and CD4 decline were suggested to be the
consequence of a persistent low-level viral replication in studies investigating immunologic
progression during HIV control [10,24,33,34]. Higher CD8 counts at ART initiation or an
increase in CD8 count during ART were predictive factors of virological treatment failure
[35,36]. Elevated CD8 counts and decreasing CD4 counts may result from persistent or
repeated low-level viremia.
One limitation of our study is the lack of confirmation of ART-naïve status as no drug dos-
age was systematically conducted. However, to prevent considering patients on ART as HICs,
we removed those who experienced suspicious concomitant and large VL decrease and CD4
increase while no ART was declared on the database. Another limitation is that we could not
study the role of different HIV subtypes on control duration since data were not complete.
Finally, it is possible that the history of viral rebounds is not complete in this database, given
the irregular VL monitoring in some patients. However, the CD4 level may have provided
information regarding the risk of virological progression in these individuals.
The evolution of recommendations regarding ART initiation may reduce the chance to
conduct studies on such a large number of HICs in the future. From a public health perspec-
tive, loss of virological control as well as occurrence of viral blips in these HICs, plead for rein-
forced recommendation of condom use in case of sexual contact, regardless of the HIV status
of the partners. From a clinical perspective, careful monitoring of untreated HICs who experi-
ence decrease of CD4 and CD4/CD8 ratio during virological control, or transient viral
rebounds, is needed.
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